SAYM BioSciences

SAYM Bio is a South Korean biotechnology company specializing in the development of microbiome-based therapeutics for metabolic diseases. The company leverages its proprietary platform, which stands for Selection and Analysis of Yeast and Microbes, to identify and characterize beneficial microbial strains that regulate metabolic pathways. Their primary focus is on treating obesity and metabolic dysfunction-associated steatohepatitis (MASH) through the use of live biotherapeutic products (LBPs). By targeting gut dysbiosis, SAYM Bio aims to provide innovative treatments that offer improved safety and efficacy compared to traditional small molecule therapies. The company's lead programs, SYB-01 and SYB-02, are currently in the pre-clinical stage of development. Founded in 2020, SAYM Bio is positioned at the intersection of microbiology and metabolic health.